Regeneron Pharmaceuticals
REGN
1,064 hedge funds and large institutions have $55B invested in Regeneron Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 93 funds opening new positions, 375 increasing their positions, 415 reducing their positions, and 110 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 22 → 22 (0)
0.39% less ownership
Funds ownership: 86.54% → 86.15% (-0.39%)
10% less repeat investments, than reductions
Existing positions increased: 375 | Existing positions reduced: 415
3% less funds holding
Funds holding: 1,095 → 1,064 (-31)
15% less capital invested
Capital invested by funds: $64.5B → $55B (-$9.45B)
15% less first-time investments, than exits
New positions opened: 93 | Existing positions closed: 110
28% less call options, than puts
Call options by funds: $666M | Put options by funds: $926M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$529M |
| 2 |
JP Morgan Chase
New York
|
+$464M |
| 3 |
Renaissance Technologies
New York
|
+$197M |
| 4 |
Morgan Stanley
New York
|
+$195M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$185M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$509M |
| 2 |
Harris Associates
Chicago,
Illinois
|
-$332M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$330M |
| 4 |
Two Sigma Investments
New York
|
-$145M |
| 5 |
Two Sigma Advisers
New York
|
-$137M |
REGN Hedge Fund Activity: Q2 2022 in Review
1,064 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2022, worth a combined $55B — down 15% from $64.5B a quarter earlier.
Sellers outnumbered buyers: 110 funds closed out of REGN and 93 opened new positions — a net loss of 17 holders — while 415 trimmed existing stakes and 375 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $529M. The largest seller was Loomis, Sayles & Company, cutting an estimated $509M.
- 1,064 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2022, down from 1,095 in Q1 2022.
- Funds reported $55B of Regeneron Pharmaceuticals stock for Q2 2022, down 15% quarter-over-quarter.
- 93 funds opened new Regeneron Pharmaceuticals positions in Q2 2022 and 110 closed out, a net change of -17 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2022 was T. Rowe Price Associates, an estimated $529M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2022 was Loomis, Sayles & Company, an estimated $509M sold.
Based on aggregated 13F filings for Q2 2022.